What is the significance of thrombocytosis and low mean corpuscular hemoglobin on a CBC and how should it be managed?

Evaluation of Thrombocytosis with Low MCH

Your CBC shows reactive thrombocytosis (platelet count 527) with borderline low MCH (25.6), most likely representing early iron deficiency, and you should undergo gastrointestinal evaluation to exclude occult blood loss while initiating iron supplementation.

Interpretation of Your Laboratory Findings

Thrombocytosis Assessment

Your platelet count of 527 × 10⁹/L represents mild thrombocytosis. The key distinction is between secondary (reactive) thrombocytosis and essential thrombocythemia (ET), a myeloproliferative neoplasm 1.

Your CBC pattern strongly suggests secondary thrombocytosis rather than ET based on:

• Normal hemoglobin (13.5 g/dL) and normal MCV (82.4 fL) argue against ET, which typically presents with higher hemoglobin and MCV 1
• Low MCH (25.6 pg) is characteristic of iron deficiency, a common cause of reactive thrombocytosis 1
• Normal RDW (14.5%) and normal MPV (10.4 fL), whereas ET patients typically show elevated RDW and MPV 1
• Absence of extreme thrombocytosis (ET typically presents with higher platelet counts) 2

Low MCH Significance

Your MCH of 25.6 pg indicates early iron deficiency, even though your hemoglobin and MCV remain normal 3. This represents the earliest stage of iron depletion before frank microcytic anemia develops 3.

Low MCH in the absence of anemia should not be dismissed, as it often precedes the development of iron deficiency anemia and may indicate ongoing occult blood loss 3.

Recommended Management Algorithm

Step 1: Iron Studies (Immediate)

Order serum ferritin and transferrin saturation 3:

• Ferritin <12 μg/dL confirms iron deficiency 3
• Ferritin <100 μg/dL with low MCH suggests iron deficiency even if not severely depleted 3
• Transferrin saturation <30% supports the diagnosis 3

Step 2: Identify Source of Iron Loss

In adults with iron deficiency and no obvious cause, gastrointestinal blood loss is the primary concern 3:

• Upper endoscopy with small bowel biopsy to exclude gastric cancer, peptic ulcer disease, and celiac disease 3
• Colonoscopy to exclude colorectal cancer, polyps, and angiodysplasia 3
• Evaluate for NSAID use, which commonly causes occult GI bleeding 3
• Consider chronic inflammatory conditions (inflammatory bowel disease) 1

Common pitfall: Assuming dietary insufficiency without excluding GI pathology—gastrointestinal malignancy may present with only mild laboratory abnormalities 3.

Step 3: Iron Replacement

Initiate oral iron supplementation (typically ferrous sulfate 325 mg daily) 3:

• Response should be evident within 3 weeks with rising reticulocyte count 3
• Continue for 3-6 months to replete iron stores 3
• Monitor CBC and ferritin to confirm response 3

Step 4: Thrombocytosis Monitoring

Your thrombocytosis will likely resolve with iron repletion 1. However:

• Recheck CBC after 3 months of iron therapy 1
• If thrombocytosis persists (platelets ≥450 × 10⁹/L) despite iron repletion, then consider molecular testing for JAK2V617F, CALR, and MPL mutations to exclude ET 1, 2
• Bone marrow biopsy is reserved for cases where molecular testing is positive or clinical suspicion for myeloproliferative neoplasm remains high 2

Step 5: Thrombosis Risk Assessment

Your current thrombosis risk is low given the mild degree of thrombocytosis and likely reactive etiology 4:

• Low-dose aspirin (81 mg daily) is reasonable if no contraindications exist, particularly given the association between low MCH and thrombotic risk in some populations 5
• Cytoreductive therapy is NOT indicated for reactive thrombocytosis 2
• If ET is ultimately diagnosed, risk stratification would determine need for cytoreductive therapy (hydroxyurea or pegylated interferon-α) 2

Key Clinical Caveats

Do not assume reactive thrombocytosis without excluding malignancy: Active malignancy, chronic inflammatory disease, and splenectomy are the strongest predictors of secondary thrombocytosis 1, but occult GI cancer may present subtly 3.

Low MCH predicts poor outcomes in multiple conditions including cardiovascular disease 6 and may indicate need for more aggressive iron repletion 5.

Approximately 50% of patients with iron deficiency are neither anemic nor microcytic at diagnosis 7, making your presentation typical for early iron depletion.